For the past 20 years, Dr. Mircea Ivan has studied the molecular responses to hypoxia. His postdoctoral work elucidated how cells monitor ambient O2 by enzymatic prolyl hydroxylation of HIF and opened the way for clinical applications of HIF stabilization.
As an independent investigator, Ivan discovered the noncoding arm of oxygen sensing and introduced the concept “hypoxia-regulated miRNAs.” In 2015, his group was the first to show that reactivation of pyruvate utilization by mitochondria enhances the antitumor effects of bevacizumab. Since 2016, he has served as senior associate editor for the J.Cell.Mol.Med. (Wiley).
Areas of Expertise
Hypoxia, oxygen-sensing, noncoding RNAs, cancer biology.